阿那白滞素与卡那奴单抗在单基因自身炎症性疾病中的药物留存率:国际AIDA注册中心观察性研究
随访12、24、48个月时IL-1抑制剂估计留存率分别为75.8%、69.7%和51.1%,不良事件是停药唯一独立危险因素,高外显率突变患者留存率更高,并观察到显著激素节约效应。
要点
- IL-1抑制剂在单基因自身炎症性疾病中48个月留存率为51.1%。
- 高外显率突变患者药物留存率显著高于低外显率变异者(P=0.015)。
核心结论
- IL-1抑制剂在单基因自身炎症性疾病中显示良好的长期药物留存率,且不受既往生物制剂治疗线数影响。
- 不良事件是治疗撤药的唯一独立预测因素,需密切监测。
- 低外显率变异患者更可能中断治疗,应重视分子诊断与突变外显率。
研究设计与样本
- 多中心回顾性观察性研究,分析国际AIDA注册中心中接受阿那白滞素或卡那奴单抗治疗的最常见单基因自身炎症性疾病患者。
主要发现
- IL-1抑制剂在随访12、24、48个月时的估计药物留存率分别为75.8%、69.7%和51.1%。
- 发生不良事件的患者药物留存率显著更低(P=0.019)。
- 生物制剂初治与既往生物制剂治疗患者间药物留存率无显著差异(P=0.985)。
- 携带高外显率突变患者药物留存率显著高于低外显率变异患者(P=0.015)。
关键数值与推荐
- 12个月药物留存率75.8%,24个月69.7%,48个月51.1%。
- 不良事件组与无不良事件组留存率差异P=0.019;高外显率突变与低外显率变异组留存率差异P=0.015。
临床怎么用
- IL-1抑制剂可用于单基因自身炎症性疾病的长期治疗,既往生物制剂暴露不影响其留存率。
- 治疗期间应密切监测不良事件,因其显著增加停药风险。
- 应重视分子诊断与突变外显率评估,低外显率变异患者需关注治疗中断可能。
局限性
- 回顾性观察性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. PATIENTS AND METHODS: Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. RESULTS: Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated DRR of IL-1 inhibitors at 12, 24 and 48 months of follow-up was 75.8%, 69.7% and 51.1%, respectively. Patients experiencing an adverse event had a significantly lower DRR (P=0.019). In contrast, no significant differences were observed between biologic-naïve patients and those previously treated with biologic drugs (P=0.985). Patients carrying high-penetrance mutations exhibited a significantly higher DRR compared with those with low-penetrance variants (P=0.015). Adverse events were the only variable associated with a higher hazard of treatment withdrawal [hazard ratio (HR) 2.573 (CI: 1.223, 5.411), P=0.013] on regression analysis. A significant glucorticoid-sparing effect was observed (P<0.0001). CONCLUSIONS: IL-1 inhibitors display an excellent long-term effectiveness in terms of DRR, and their survival is not influenced by the biologic line of treatment. They display a favourable safety profile, which deserves, however, a close monitoring given its impact on treatment continuation. Special attention should be paid to molecular diagnosis and mutation penetrance, as patients carrying low-penetrance variants are more likely to interrupt treatment.
引用
- Sota J, Rigante D, Cimaz R, et al. Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. Rheumatology (Oxford). 2021. PMID: 33961014. doi:10.1093/rheumatology/keab419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。